Fine Line Between Clear and Almost Clear Psoriasis Severity

Article

Understanding the difference between clear and almost clear skin is crucial with the advent of new biologic therapies that make complete clearance attainable.

Understanding the difference between clear and almost clear skin is crucial with the advent of new biologic therapies make complete clearance attainable.

Researchers presented comparisons in patient perceptions of the severity of psoriasis signs of moderate-to-severe plaque psoriasis that achieved complete skin clearance (sPGA 0) and almost clear skin (sPGA 1) based on Psoriasis Symptom Inventory (PSI) scores at the American Academy of Dermatology 2015 Annual meeting in San Francisco, CA.

Physicians routinely assess psoriasis severity with the static Physician’s Global Assessment, through which treatment response is typically defined as achieving a sPGA of 0 or 1.

A total of 295 adult patients with moderate-to-severe psoriasis receiving a biologic were enrolled in this cross-sectional, observational study. Upon completing 8-item PSI electronic daily diary on 7 consecutive days (Day 1-7), changes in sPGA status in some patients excluded 65 individuals.

Of the sPGA 0 subjects, 60.8% reported a PSI=0 compared with 5.3% who had sPGA 1. Furthermore, approximately 95% of sPGA 0 patients met the PSI responder threshold compared with 54.3% with sPGA 1.

Researchers concluded, “A significantly higher proportion of patients with skin clearance (sPGA0) reported no psoriasis symptom severity compared to patients rated as ‘almost clear’ (sPGA 1). A significantly higher proportion of sPGA 0 patients (95%) also achieved not at all (0) or mild (1) psoriasis severity on all 8 PSI signs and symptoms compared with sPGA 1 patients (54%).”

Physician assessments indicated, patients who were considered ‘clear’ reported either no severity or significantly lower severity of psoriasis signs and symptoms than those rated as ‘almost clear’.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
Should We Reclassify Diabetes Subtypes?
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
© 2024 MJH Life Sciences

All rights reserved.